Advances with support vector machines for novel drug discovery. (2nd January 2019)

• Record Type: Journal Article
• Authors: Maltarollo, Vinicius Gonçalves; Kronenberger, Thales; Espinoza, Gabriel Zarzana; Oliveira, Patricia Rufino; Honorio, Kathia Maria
• Is Part Of: Expert opinion on drug discovery. Volume 14:Number 1(2019:Jan.)
• Page Start: 23
• Page End: 33
• Publication Date: 2019-01-02
• Subjects: Drug discovery -- medicinal chemistry -- machine learning -- support vector machines -- QSAR -- classification -- virtual screening; 615.1
• DOI: 10.1080/17460441.2019.1549033
• Languages: English
• ISSNs: 1746-0441

Abstract

ABSTRACT: Introduction : Novel drug discovery remains an enormous challenge, with various computer-aided drug design (CADD) approaches having been widely employed for this purpose. CADD, specifically the commonly used support vector machines (SVMs), can employ machine learning techniques. SVMs and their variations offer numerous drug discovery applications, which range from the classification of substances (as active or inactive) to the construction of regression models and the ranking/virtual screening of databased compounds. Areas covered : Herein, the authors consider some of the applications of SVMs in medicinal chemistry, illustrating their main advantages and disadvantages, as well as trends in their utilization, via the available published literature. The aim of this review is to provide an up-to-date review of the recent applications of SVMs in drug discovery as described by the literature, thereby highlighting their strengths, weaknesses, and future challenges. Expert opinion : Techniques based on SVMs are considered as powerful approaches in early drug discovery. The ability of SVMs to classify active or inactive compounds has enabled the prioritization of substances for virtual screening. Indeed, one of the main advantages of SVMs is related to their potential in the analysis of nonlinear problems. However, despite successes in employing SVMs, the challenges of improving accuracy remain.